ASH 2025 Abstracts are out!: Ferma Congress Analysis

The 67th American Society of Hematology (ASH) Annual Meeting is happening in Orlando, Florida from December 6-9, 2025. Over 7,400 world-class oral presentations, poster sessions, educational programs, and scientific workshops will take place in the span of four days, in a hybrid in-person/virtual format.

ASH has released the abstracts as of November 2025, and Ferma Congress has analyzed all 6,425 abstracts, alongside social media buzz and clinical trial registries, to identify the most relevant and highly anticipated sessions among hematologists and oncologists. The priority sessions span five major therapeutic areas:

• Acute Myeloid Leukemia (AML) - 859 Presentations
• Multiple Myeloma (MM) - 651 Presentations
• Sickle Cell Disease (SCD) - 354 Presentations
• Lymphomas (DLBCL, CLL, Follicular) - 591 Presentations
• Myelodysplastic Syndromes (MDS) - 233 Presentations

1. Acute Myeloid Leukemia (AML): The Reign of Venetoclax Continues

With 859 presentations, AML remains a major focus. Venetoclax features prominently, with 230 presentationshighlighting its expanding role as the backbone of AML therapy, with extensive data across newly diagnosed, relapsed/refractory, and maintenance settings.

What to Watch: Keep an eye on emerging combination strategies that are pushing the boundaries of treatment, including novel pairings with Menin inhibitors and FLT3 inhibitors.

Key Trial Updates to Watch:

• NCT04703686 - 9 presentations (most-cited AML trial at ASH 2025)
• NCT02736357 - 7 presentations with pivotal readouts

Emerging Combination Strategies:

• FLT3 inhibitors + venetoclax in FLT3-mutated AML (novel data on gilteritinib, quizartinib combinations)
• IDH inhibitors + venetoclax in IDH1/2-mutated disease (enasidenib, ivosidenib combinations)
• Menin inhibitors + venetoclax (breakthrough data in NPM1-mutated AML)
• Novel triplet regimens for relapsed/refractory patients
• Allogeneic stem cell transplantation optimization (82 presentations on HSCT strategies)

Key Takeaway: Venetoclax-based combinations are emerging as promising candidates for establishing new standards of care in AML. The sheer volume of data at ASH 2025 confirms their central role in the AML treatment landscape.

2. Multiple Myeloma (MM): CAR T-Cell Therapy and the Challenge of Access

The Multiple Myeloma space, with 651 presentations, is being redefined by cellular therapies. CAR T-cell therapy is a dominant topic (106 presentations), with a strong focus on real-world evidence and its strategic use in earlier lines of treatment. However, this progress is shadowed by a growing concern: geographic disparities in patient access to these transformative treatments.

• Pivotal Trials: Don't miss the latest data from the DREAMM-7 and DREAMM-8 trials, which explore the efficacy of Belantamab mafodotin in powerful new combinations.
• Emerging Players: Bispecific antibodies and other key agents are also making waves, promising new avenues for patients.

Key Takeaway: The evolution of MM treatment is rapid. While CAR-T therapies are moving up in treatment algorithms, ensuring equitable access for all patients is becoming a critical challenge for the entire community.

3. Sickle Cell Disease (SCD) & Hemoglobinopathies: A Curative Era Begins

This year marks a pivotal moment for Sickle Cell Disease research, with 354 presentations. The field is shifting dramatically from supportive care to potentially curative therapies, led by groundbreaking advances in gene therapy.

• Groundbreaking Data: A must-see abstract (25-13543) from the Children's Hospital of Philadelphia and the University of Pennsylvania will present a comparative analysis of biomarkers across different beta-thalassemia treatments. This study compares gene-modified HSCT, allogeneic HSCT, and other treatments, offering a clear look at their effects on the underlying biology of the disease.

Key Takeaway: Gene-modified therapies are achieving results nearly identical to allogeneic HSCT, establishing them as a true curative option. While this ushers in an era of hope, significant healthcare disparities remain a barrier to equitable access.

4. Lymphomas (DLBCL, CLL, & Follicular): The Shift to Chemotherapy-Free Regimens

Across all major lymphomas (591 total presentations), a clear trend is emerging: the move away from traditional chemotherapy.

• Diffuse Large B-Cell Lymphoma (DLBCL): Innovation is being driven by bispecific antibodies, which are showing promise in various patient populations.
• Chronic Lymphocytic Leukemia (CLL): The focus is on next-generation BTK inhibitors and the strategic use of Minimal Residual Disease (MRD) to guide therapy.
• Follicular Lymphoma (FL): The push towards effective, chemotherapy-free approaches continues to gain momentum.

Key Takeaway: Targeted therapies are rapidly transforming lymphoma treatment. Bispecific antibodies and advanced BTK inhibitors are at the forefront of this paradigm shift, offering new hope for patients.

5. Myelodysplastic Syndromes (MDS): Precision Medicine Takes Center Stage

With 233 presentations, the MDS field is moving decisively beyond hypomethylating agents (HMAs). The future lies in novel combination strategies and a deeper understanding of molecular profiling to tailor treatments.

Key Takeaway: The era of one-size-fits-all treatment for MDS is ending. The focus is now on precision medicine, using molecular data to guide the selection of novel agents that can expand options for patients.

Additional Hot Topics to Watch

• Venous Thromboembolism (VTE): A major meta-analysis (Abstract 25-10028) of five randomized controlled trials is set to provide a definitive answer on the safety and efficacy of reduced-dose DOACs for extended VTE treatment. Early results suggest these lower doses significantly reduce bleeding risk without compromising effectiveness.
• Systemic Amyloidosis: A fascinating longitudinal study (Abstract 25-13559) analyzing two decades of real-world data (2005-2025) reveals dramatic improvements in mortality, especially for advanced-stage patients. The data highlights how earlier diagnosis and the increased use of therapies like daratumumab have transformed patient outcomes.

Navigating the Data Overload at ASH 2025

With thousands of sessions packed into just four days, keeping up with critical intelligence is a monumental task. To truly harness the power of this event and transform the flood of information into a competitive advantage, a new approach is needed.

The rapid analysis of abstracts you've just read-synthesizing key trends, emerging therapies, and competitive insights-is exactly the kind of intelligence that Ferma Congress makes possible. These insights are just the tip of the iceberg.

At Ferma Congress, we specialize in providing comprehensive, AI-powered coverage of major medical conferences like ASH. Our platform offers real-time analysis, ensuring you never miss the data that matters most all while delivering insights faster and at a fraction of the cost of traditional methods.

To learn more about how to enhance your conference coverage, book a 30-minute consultation with us today.